A prospective open‐label clinical trial of adalimumab for the treatment of hidradenitis suppurativa

Amano, Masahiro; Grant, Annika; Kerdel, Francisco A.

doi:10.1111/j.1365-4632.2010.04545.x

Cited by 79 publications

(93 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, after 12 weeks of treatment no difference could be observed compared with baseline or with placebo. Nonetheless, these studies report on high recurrence rates after discontinuation [75,76]. It has been suggested that a weekly dose is more effective [3].…”

Section: Adalimumabmentioning

confidence: 99%

See 1 more Smart Citation

An Update on Medical Treatment Options for Hidradenitis Suppurativa

Deckers

Prens

2015

Drugs

View full text Add to dashboard Cite

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease characterized by recurrent inflammatory nodules mostly located in the armpits and groin. Over the years multiple treatments for HS have been proposed; however, to date a cure is still lacking. In this update we provide an overview of most drug treatments reported on for HS, where possible with their mode of action and side effects. In mild cases, clindamycin lotion or resorcinol cream have proven effective. Tetracyclines are a first-line systemic option in more widespread or severe cases, followed by the combination of clindamycin and rifampicin. However, the recurrence rate is high after discontinuation of clindamycin plus rifampicin combination therapy. Long-term treatment with retinoids, especially acitretin is feasible, although teratogenicity has to be taken into account in females of reproductive age. Multiple antiinflammatory drugs have been suggested for HS, such as dapsone, fumarates or cyclosporine. However, their effectiveness in HS is based on small case series with varying results. If most common treatments have failed, biologics (e.g., infliximab or adalimumab) are the next step. Although not addressed in this review, surgical interventions are often needed to achieve remission. Key PointsHidradenitis suppurativa (HS) is a chronic inflammatory skin disease without a cure.Antibiotics (topical or oral) are often the first treatment option for HS.In cases of more extensive or therapy-resistant HS, biologicals (e.g., infliximab or adalimumab) are a good therapeutic option.

show abstract

Section: Adalimumabmentioning

confidence: 99%

“…Over the years multiple studies followed, reporting different clinical outcomes. Two prospective studies using a dose of 40 mg every other week showed initial improvement [75,76]. However, after 12 weeks of treatment no difference could be observed compared with baseline or with placebo.…”

Section: Adalimumabmentioning

confidence: 99%

An Update on Medical Treatment Options for Hidradenitis Suppurativa

Deckers

Prens

2015

Drugs

View full text Add to dashboard Cite

show abstract

“…There are several scoring systems for assessing disease severity (Hurley staging, HS-Physician's Global Assessment [PGA], the modified Sartorius score [MSS], Hidradenitis Suppurativa Severity Index [HSSI]) (Table 1) [16,17,18,19]; however, all of them have some limitations in daily practice [20]. …”

Section: Classification and Severity Assessmentmentioning

confidence: 99%

Medical and Surgical Treatment of Hidradenitis Suppurativa: A Review

Scuderi

Monfrecola

Dessy

et al. 2017

Skin Appendage Disord

View full text Add to dashboard Cite

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease presenting with painful nodules, abscesses, sinus tracts, and scarring primarily affecting apocrine gland-rich intertriginous areas. HS prevalence ranges from 0.05 to 1%. The central pathogenic event in HS is believed to be the occlusion of the upper part of the folliculopilosebaceous unit, leading to the rupture of the sebofollicular canal with the consequent development of perifollicular lymphohistiocytic inflammation. The HS treatment choices are influenced by disease severity and its individual subjective impact, involving both medical and surgical interventions. However, given the chronic nature of HS, its destructive impact on social, working, and daily life of patients, its management is often frustrating for both the patient and physician. Hence, prompt and effective management strategies are urgently needed and a multidisciplinary approach is advocated. Therefore, in this article, we highlighted the main features of HS (clinical aspects, epidemiology, pathogenesis, diagnostic criteria, classifications, comorbidities, and treatments), so that awareness of this disease might be heightened in primary care physicians and surgeons, who may be the first health care providers to see patients with this disease owing to its characteristic clinical presentation (inflammatory nodules, abscesses, sinus tract, etc.).

show abstract

“…Regarding adalimumab, in both case reports and more extensive studies, an improvement in HS lesions was observed between 4 and 12 weeks of treatment, and the results were maintained for the duration of therapy, despite increasing doses specified in some reports [7,8,9,10,11,12,13,14,15,16,17,18] (data summarized in table 3). Therefore, adalimumab treatment seems to have a favorable outcome in the treatment of HS, with improvement somewhat slower than with infliximab, but maintained over time, with a high safety profile.…”

Section: Review and Discussionmentioning

confidence: 99%

“…Therefore, adalimumab treatment seems to have a favorable outcome in the treatment of HS, with improvement somewhat slower than with infliximab, but maintained over time, with a high safety profile. The main secondary adverse event was edema at the site of injection; other serious adverse effects were exceptional [7,8,9,10,11,12,13,14,15,16,17,18,19,20,21]. Miller et al [20] conducted a double-blind placebo-controlled study which included 15 patients who received adalimumab 80 mg at week 1 and 40 mg eow for 12 weeks; 6 remaining patients were given a placebo.…”

Section: Review and Discussionmentioning

confidence: 99%

Management of Hidradenitis Suppurativa with Biological Therapy: Report of Four Cases and Review of the Literature

et al. 2014

View full text Add to dashboard Cite

Several studies report the usefulness of different biological therapies in the management of a difficult-to-treat pathology such as hidradenitis suppurativa (HS). However, there are little data on this, which shows the great difficulty in the management of this disease. We will report herein our experience of the treatment of four complex cases of HS. We will also review previous cases published in the literature in order to further assess the results obtained with different biological drugs in terms of efficacy and safety. We conclude that, in the near future, biological therapy could become an essential tool in the management of cases of HS who have not previously responded to classical treatment.

show abstract

A prospective open‐label clinical trial of adalimumab for the treatment of hidradenitis suppurativa

Abstract: Our study demonstrated statistically clinical improvement is not observed in the treatment of HS with adalimumab. Future studies using higher doses of adalimumab are warranted.

Cited by 79 publications

References 15 publications

An Update on Medical Treatment Options for Hidradenitis Suppurativa

An Update on Medical Treatment Options for Hidradenitis Suppurativa

Medical and Surgical Treatment of Hidradenitis Suppurativa: A Review

Management of Hidradenitis Suppurativa with Biological Therapy: Report of Four Cases and Review of the Literature

Contact Info

Product

Resources

About